五肽 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Contains two non-natural residues |
| Molecular formula | C38H49N9O5 | Free base form |
| Molecular weight | 711.85 g/mol | Calculated from formula |
| Primary target | GHS-R1a ghrelin receptor | Agonist activity |
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Although a majority of OECD countries protect the right of employees to vote for directors on boards of corporations (usually at least one-third), Australia has not yet passed a general law by amending the Corporations Act 2001, the Fair Work Act 2009 or state laws for worker directors. However, Australia does have board-level employee representation (or "codetermination") in occupational pensions, and several specific sectors. First, under the Hawke-Keating government Australia enacted a leading model for voice in worker's capital, now in the Superannuation Industry (Supervision) Act 1993 section 89, requiring an "equal numbers of employer representatives and member representatives" on the board of directors or trustees in a super-fund. In 2010 a proposal was made to amend this for so called "independent directors" to be required to take the balance of power, appointed by the incumbent board, even though the evidence suggested this would be a step backwards. No changes were passed. There is not yet express legislation to require that asset managers, to whom investment and shareholder voting was outsourced, must follow the voting policies set by elected representatives on superannuation fund boards, as is found in Switzerland.
In the next scene a messenger recounts Glauce and Creon's deaths. When the children arrived with the robes and coronet, Glauce gleefully put them on and went to find her father. The poison overtook her and she fell to the floor, dying horribly and painfully. Creon clutched her tightly as he tried to save her and, by coming in contact with the robes and coronet, was poisoned and died as well.
==== Economy ==== According to the World Bank's Lebanon Rapid Damage and Needs Assessment (RDNA) 2025 report, the conflict cost Lebanon a total of US$14 billion. Physical damages amounted to $6.8 billion, while decreased productivity, lost revenue, and operational costs amounted to $7.2 billion. With $4.6 billion in damages, the housing sector suffered the most losses, followed by the commerce, industry, and tourism sector with losses of $3.4 billion. The conflict caused Lebanon's real GDP to decline by 7.1% in 2024. The World Bank added that reconstruction costs amounted to $11 billion.
Long-term storage of radioactive waste requires the stabilization of the waste into a form that will neither react nor degrade for extended periods. It is theorized that one way to do this might be through vitrification. Currently at Sellafield, the high-level waste (PUREX first cycle raffinate) is mixed with sugar and then calcined. Calcination involves passing the waste through a heated, rotating tube. The purposes of calcination are to evaporate the water from the waste and de-nitrate the fission products to assist the stability of the glass produced. The 'calcine' generated is fed continuously into an induction heated furnace with fragmented glass. The resulting glass is a new substance in which the waste products are bonded into the glass matrix when it solidifies. As a melt, this product is poured into stainless steel cylindrical containers ("cylinders") in a batch process. When cooled, the fluid solidifies ("vitrifies") into the glass. After being formed, the glass is highly resistant to water. After filling a cylinder, a seal is welded onto the cylinder head. The cylinder is then washed. After being inspected for external contamination, the steel cylinder is stored, usually in an underground repository. In this form, the waste products are expected to be immobilized for thousands of years. The glass inside a cylinder is usually a black glossy substance. All this work (in the United Kingdom) is done using hot cell systems. Sugar is added to control the ruthenium chemistry and to stop the formation of the volatile RuO4 containing radioactive ruthenium isotopes.
Sources: en.wikipedia.org
Nicotine is a very hygroscopic, colorless to pale yellow, oily liquid that gradually turns brown on exposure to air or light. It develops a characteristic pungent, fishy odor of pyridine and has an acrid burning taste. Pure nicotine tastes "terrible". It is very soluble in alcohol, chloroform, ether, light petroleum, kerosene, or oils. It is miscible with water in its neutral amine base form between 60 °C and 210 °C. It is a dibasic nitrogenous base, having Kb1=1×10−6, Kb2=1×10−11. It readily forms ammonium salts with acids that are usually solid and water-soluble. Its flash point is 95 °C, and its auto-ignition temperature is 244 °C. Nicotine is volatile (vapor pressure 5.5 Pa at 25 °C) On exposure to ultraviolet light or various oxidizing agents, nicotine is converted to nicotine oxide, nicotinic acid (niacin, a B3 vitamer), and methylamine. Anabasine is a structural isomer of nicotine, as both compounds have the molecular formula C10H14N2.
At temperatures greater than 44 °C (111 °F), proteins begin losing their three-dimensional shape and start breaking down. This results in cell and tissue damage. Many of the direct health effects of a burn are caused by failure of the skin to perform its normal functions, which include: protection from bacteria, skin sensation, body temperature regulation, and prevention of evaporation of the body's water. Disruption of these functions can lead to infection, loss of skin sensation, hypothermia, and hypovolemic shock via dehydration (i.e. water in the body evaporated away). Disruption of cell membranes causes cells to lose potassium to the spaces outside the cell and to take up water and sodium. In large burns (over 30% of the total body surface area), there is a significant inflammatory response. This results in increased leakage of fluid from the capillaries, and subsequent tissue edema. This causes overall blood volume loss, with the remaining blood suffering significant plasma loss, making the blood more concentrated. Poor blood flow to organs like the kidneys and gastrointestinal tract may result in kidney failure and stomach ulcers. Increased levels of catecholamines and cortisol can cause a hypermetabolic state that can last for years. This is associated with increased cardiac output, metabolism, a fast heart rate, and poor immune function.
=== United States === A CDC report for the period 2017–2019 found that 41% of outbreaks at restaurants were caused by a sick employee. Contributory factors identified included lack of written policy compliance with FDA recommendations for identifying red-flag symptoms, glove use, and hand washing; lack of paid sick leave at the majority of establishments; and social pressure to come to work even while sick. The remaining outbreaks had a variety of causes, including inadequate cooking, improper temperature, and cross-contamination. In the United States, using FoodNet data from 2000 to 2007, the CDC estimated there were 47.8 million foodborne illnesses per year (16,000 cases for 100,000 inhabitants) with 9.4 million of these caused by 31 known identified pathogens.
== Bibliography == Baur, F. J.; Lange, W. (1951). "Directed Interesterification in Glycerides. III. The Synthesis of Single-Fatty Acid 1,3-Diglycerides". Journal of the American Chemical Society. 73 (8): 3926–3928. doi:10.1021/ja01152a109. Russell, Robert M.; Yeager, Robert; Baur, Fred; Dupre, James R. (November 1976). "Bird Problems and Food Storage and Processing Facilities". Bird Control Seminars Proceedings. Lincoln: University of Nebraska. Baur, F. J., ed. (1984). Insect Management for Food and Storage and Processing. St. Paul, Minnesota: American Association of Cereal Chemists. ISBN 0913250384. US patent US3498798A, Fredric J Baur, Harold Kenneth Hawley & Harold Kenneth Hawley, "Packaging of chip-type snack food products", published March 3, 1970, issued March 3, 1970, assigned to Procter and Gamble Co
Five years later, GSK shuttered the Sirtris program without successful drug development. In 2006, Sinclair co-founded Genocea Biosciences, a company founded based on the work of Harvard scientist Darren E. Higgins around antigens that stimulate T cells and the use of these antigens to create vaccines; The company delisted from the NASDAQ and closed in 2022 due to lack of funding. In 2008, Sinclair was promoted to tenured professor at Harvard Medical School. A few years later, he also became a conjoint professor at the School of Medical Sciences at the University of New South Wales. In 2008, he also joined the scientific advisory board of Shaklee and helped them devise and introduce a product containing resveratrol called "Vivix". He later disputed the use of his name and words to promote the supplement, and resigned from the board. In 2011, Sinclair co-founded OvaScience along with Michelle Dipp, Aldrich, Westphal, and Jonathan Tilly. The company was based on scientific work done by Tilly concerning mammalian oogonial stem cells and work on mitochondria by Sinclair. The company merged with Millendo Therapeutics in 2018. In 2011, he also co-founded CohBar along with Nir Barzilai and other colleagues. CohBar aimed to discover and develop novel peptides derived from mitochondria. CohBar delisted from the NASDAQ upon belief that it was a public shell. In 2015, he co-founded Metro Biotech along with Washington University in St. Louis professor Dr. Rajendra Apte. The pharmaceutical company focused on NAD+ precursors such as NMN.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.
It acts as an agonist at the growth hormone secretagogue receptor, also known as the ghrelin receptor. Binding at pituitary somatotroph cells promotes growth hormone release.
Early studies report weaker effects on cortisol, prolactin, and appetite than compounds such as GHRP-6. The size of that difference in humans is not firmly established.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.